Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetracosactide for Post-Dural Puncture Headache
NCT02813655Phase 2Terminated
- Sponsor
- Hospices Civils de Lyon
- Start
- Oct 2016
- Primary completion
- Nov 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tetracosactide hexaacetate in post-dural puncture headache (PDPH) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Rate of blood patch use at Day 15. Started Oct 2016; status: terminated.
02
Drugs
tetracosactide hexaacetate
03
Conditions
post-dural puncture headache (PDPH)
Beyond the preview
Go deeper on NCT02813655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813655.